• Explore /
  • Poster
  • / Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Abstract Poster

Authors

null

Matthew Raymond Smith

Massachusetts General Hospital, Boston, MA

Matthew Raymond Smith , Johann Sebastian De Bono , Cora N. Sternberg , Sylvestre Le Moulec , Stephane Oudard , Ugo De Giorgi , Michael Krainer , Andre M. Bergman , Wolfgang Hoelzer , Ronald De Wit , Martin Boegemann , Fred Saad , Giorgio Cruciani , Antoine Thiery- Vuillemin , Susan Feyerabend , Kurt Miller , David Albert Ramies , Colin Hessel , Aaron Weitzman , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01605227

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 139)

DOI

10.1200/jco.2015.33.7_suppl.139

Abstract #

139

Poster Bd #

A5

Abstract Disclosures

Similar Posters

First Author: Ethan M. Basch

First Author: Thomas W. Flaig

First Author: Karen A. Autio

First Author: Joaquin Mateo